Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide, Umbralisib, and Ublituximab in R/R iNHL or MCL
NCT04635683Phase 1Withdrawn
- Start
- Sep 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules, Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of lenalidomide, umbralisib and ublituximab in Indolent Non-Hodgkin Lymphoma (INHL) and mantle cell lymphoma (MCL). Primary endpoint: Recommended Phase 2 Dose. Planned start Sep 2022; status: withdrawn.
02
Drugs
lenalidomideumbralisibublituximab
03
Conditions
Indolent Non-Hodgkin Lymphoma (INHL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT04635683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04635683.